Vistagen Therapeutics, Inc. (VTGN) stock
VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3076% below fair value
$0.20+0.01 (+6.12%)
Close on Nov 18, 2026Market cap $8.85MP/E –Yield –
Vistagen Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Vistagen Therapeutics's free cash flow for the twelve months ending Mar 31, 2023 was -$50.24M. For fiscal 2024 it was -$25.81M. The highest annual figure on record is -$4.83M in fiscal 2016.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Mar 31, 2024 | -$25.81M | – |
| FY2023 | Mar 31, 2023 | -$50.24M | – |
| FY2022 | Mar 31, 2022 | -$45.26M | – |
| FY2021 | Mar 31, 2021 | -$12.35M | – |
| FY2020 | Mar 31, 2020 | -$15.76M | – |
| FY2019 | Mar 31, 2019 | -$14.70M | – |
| FY2018 | Mar 31, 2018 | -$9.06M | – |
| FY2017 | Mar 31, 2017 | -$7.50M | – |
| FY2016 | Mar 31, 2016 | -$4.83M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -$7.79M | – |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -$9.95M | – |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -$16.37M | – |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -$16.14M | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -$15.39M | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -$12.05M | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -$11.50M | – |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -$6.32M | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -$5.31M | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -$2.81M | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -$3.73M | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -$3.91M | – |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -$2.60M | – |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -$2.45M | – |
See a number that looks wrong?